{"id":"NCT01854645","sponsor":"Pearl Therapeutics, Inc.","briefTitle":"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","officialTitle":"A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05","primaryCompletion":"2015-02","completion":"2015-02","firstPosted":"2013-05-15","resultsPosted":"2017-03-28","lastUpdate":"2017-03-28"},"enrollment":2103,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"GFF MDI","otherNames":[]},{"type":"DRUG","name":"GP MDI","otherNames":[]},{"type":"DRUG","name":"FF MDI","otherNames":[]},{"type":"DRUG","name":"Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)","otherNames":[]},{"type":"DRUG","name":"Placebo MDI","otherNames":[]}],"arms":[{"label":"GFF MDI","type":"EXPERIMENTAL"},{"label":"GP MDI","type":"EXPERIMENTAL"},{"label":"FF MDI","type":"EXPERIMENTAL"},{"label":"Open-label tiotropium bromide inhalation powder","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The overall objective of this study is to assess the efficacy and safety of treatment with PT003 (GFF MDI), PT005 (FF MDI), PT001 (GP MDI), and open-label tiotropium bromide inhalation powder compared with each other and Placebo MDI over 24 weeks in subjects with moderate to very severe COPD.","primaryOutcome":{"measure":"Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24","timeFrame":"Baseline and at Week 24","effectByArm":[{"arm":"GFF MDI (PT003)","deltaMin":0.126,"sd":null},{"arm":"GP MDI (PT001)","deltaMin":0.066,"sd":null},{"arm":"FF MDI (PT005)","deltaMin":0.062,"sd":null},{"arm":"Spiriva® Handihaler® (Open-label)","deltaMin":0.105,"sd":null},{"arm":"Placebo","deltaMin":-0.024,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":139,"countries":["United States","Australia","New Zealand"]},"refs":{"pmids":["35815359","32450869","32021148","28720336"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4154&filename=PT003006-02%20Protocol%20Amendment-FINAL-11Sept14_29Jun16_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":526},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Dyspnoea"]}}